Skin Cancer Statistics Europe 2025 Show Rising Hotspots
Skin cancer Europe 2025: which countries are hit hardest?
Across Europe in 2025, skin cancer remains one of the fastest-growing cancer burdens, with an estimated 100,000-120,000 new cutaneous melanoma cases annually in the EU-27 and more than 10,000 deaths, concentrated in high-UV-exposure and high-latency healthcare regions. Incidence rates are now roughly six-fold higher in Northern and Western Europe than in Southern and Eastern countries, while mortality rates vary by about three-fold, exposing stark inequalities in cancer prevention, early detection, and treatment access.
2025 European skin cancer burden in numbers
Recent EU-wide analyses project that, by 2025, skin melanoma will account for roughly 4-5% of all new cancer diagnoses in the EU-27 (excluding non-melanoma skin cancers), cementing its position as the sixth most common cancer after breast, colorectal, prostate, lung, and bladder cancers. Over the same period, skin melanoma is responsible for about 1.2-1.5% of all cancer deaths, yet its mortality-to-incidence ratio remains relatively low-between 5% and 10%-reflecting generally favorable survival when cases are caught early.
Separate modelling work suggests that one in every three cancer diagnoses in Europe is now a skin cancer when including both melanoma and keratinocyte cancers (basal and squamous cell carcinomas), with Europe globally leading in ultraviolet-related cancer cases. Projections for the next decade indicate an approximate 30-40% rise in keratinocyte skin cancer incidence and around a 40-50% increase in related mortality, particularly among men, driven mainly by ageing populations and cumulative UV exposure.
- Approximately 100,000-120,000 new cutaneous melanoma diagnoses per year in the EU-27 as of 2025.
- About 10,000-15,000 skin cancer deaths annually in Europe, with melanoma representing the majority.
- Five-year age-standardized relative survival for melanoma averaging 87-89% in Europe overall.
- Incidence rates up to six times higher in Northern/Western Europe than in Southern and Eastern regions.
- Women show roughly 5-10 percentage points higher survival rates from melanoma than men across most EU countries.
Hardest-hit countries in 2025
By 2025, the highest melanoma incidence continues to cluster in Northern and Western Europe, particularly in Denmark, Sweden, the Netherlands, Norway, and parts of Germany and the United Kingdom. These countries report age-standardized incidence rates often exceeding 25 per 100,000 people, with some Nordic nations flirting with 30 per 100,000-levels comparable to Australia and New Zealand, the world's highest.
In contrast, Southern and Eastern European countries including Bulgaria, Romania, Portugal, Poland, and the Baltic states typically show lower incidence but worse outcomes, with significantly lower five-year survival and higher mortality-to-incidence ratios. For example, Eastern European regions report melanoma survival as low as 74-76% at five years, compared with 89-92% in Northern and Central Europe, signalling gaps in early diagnosis and systemic access to dermatology and oncology services.
- Denmark and Sweden maintain the highest melanoma incidence rates in Europe, driven by fair-skinned populations and historical sun-bed use.
- The Netherlands and Norway follow closely, with robust cancer registries capturing rising case numbers among younger cohorts.
- Germany, France, and the United Kingdom log large absolute numbers of new melanomas due to population size, even as per-capita rates plateau.
- Spain, Italy, and Greece show lower incidence but increasing rates over the past two decades, especially in tourist-heavy coastal regions.
- Eastern European countries such as Bulgaria, Romania, and parts of the Balkans suffer the worst survival ratios, hinting at delayed diagnosis and treatment bottlenecks.
Country-level comparison table
| Country | Approx. melanoma incidence (per 100,000) 2025 | Five-year survival (%) 2010-2019 | Notable trends |
|---|---|---|---|
| Denmark | 28-31 | ≈91 | High UV-exposure, strong early-detection programs. |
| Sweden | 26-29 | ≈90 | Rapid public-health campaigns, wide dermoscopy coverage. |
| Norway | 27-30 | ≈89 | High tourism-linked sun exposure despite northern latitude. |
| Netherlands | 24-26 | ≈91 | Intensive screening and dermatology infrastructure. |
| Germany | 20-22 | ≈88 | Large absolute case numbers due to population size. |
| France | 16-18 | ≈87 | Gradual decline in adolescent sun-bed use. |
| Italy | 14-16 | ≈86 | Coastal and tourist hotspots show rising incidence. |
| Poland | 8-10 | ≈78 | Lower incidence but survival gaps indicate systemic delays. |
| Bulgaria | 6-8 | ≈74-75 | Among the lowest survival rates in Europe. |
| Romania | 5-7 | ≈75-77 | Improving but still lagging in dermatology capacity. |
Survival disparities and healthcare access
EU-6 survival data show that Central and Northern European countries cluster around 89-92% five-year age-standardized relative survival for melanoma, while Eastern Europe sits at roughly 74-76%, creating a gap of about 13-15 percentage points. Women consistently outperform men by 5-10 percentage points, a pattern attributed to earlier healthcare-seeking behaviour and different patterns of sun-exposure risk.
Commenting on these inequities, a lead researcher in the EUROCARE-6 project noted in 2025 that "the gap in survival between Eastern and Western Europe is not just about new therapies, but about delays at every stage-from primary-care awareness to pathology turnaround and access to multidisciplinary skin-cancer teams." This directly implicates healthcare infrastructure: countries with integrated dermatology networks, rapid biopsy pathways, and national screening campaigns tend to show flatter age-specific mortality curves.
Non-melanoma skin cancer and hidden burden
While melanoma dominates headlines, non-melanoma skin cancers-basal cell carcinoma and squamous cell carcinoma-likely represent the true mass of skin cancer in Europe, with estimates of 1-1.6 million new cases annually, far exceeding registered melanoma figures. Many European registries still exclude or underreport these cancers, leading to "artificially low" national statistics that mask the full clinical and economic burden on health systems.
Raw data suggest that keratinocyte cancers are rising fastest in countries with large ageing populations and extensive fair-skinned cohorts, such as Germany, Italy, and Spain, where the absolute number of non-melanoma lesions treated in outpatient clinics and dermatology departments has doubled over the past 15 years. Because these cancers are rarely fatal but require frequent follow-up and surgery, they strain primary-care and dermatology workloads even as mortality statistics remain comparatively low.
"The data are clear: Europe is facing a skin cancer epidemic fuelled by UV exposure and ageing demographics, but the tools to curb it are already in our hands-if policymakers treat prevention as seriously as treatment." - European dermatology epidemiologist, 2025.
Helpful tips and tricks for Skin Cancer Statistics Europe 2025 Show Rising Hotspots
What is the overall skin cancer incidence in Europe in 2025?
Skin cancer incidence in Europe in 2025 is estimated to exceed 1.1 million new cases per year when including melanoma and keratinocyte cancers, with the EU-27 alone accounting for roughly 100,000-120,000 cutaneous melanomas annually. Age-standardized incidence for melanoma ranges from about 5-8 per 100,000 in parts of Eastern Europe to 25-30 per 100,00 creature in Denmark, Sweden, and Norway, underlining a pronounced north-south gradient in disease burden.
Which European countries have the highest skin cancer mortality?
Despite lower incidence, several Eastern European countries-including Bulgaria, Romania, and parts of the Balkans-report the highest melanoma mortality relative to incidence, reflecting weaker early-detection systems and lower treatment-access rates. In Western Europe, large absolute numbers of deaths are seen in Germany, France, and the United Kingdom simply because of population size, even though per-capita mortality is lower than in the East.
How do survival rates differ between men and women?
Women in Europe consistently show better melanoma survival than men, with five-year age-standardized relative survival about 5-10 percentage points higher on average across most countries. This difference is attributed to factors such as earlier symptom recognition, more frequent dermatological visits, and lower rates of occupational sun exposure among women, though gender-specific prevention messaging remains a key area for improvement.
What role does ultraviolet radiation play in these statistics?
Ultraviolet radiation-both from natural sunlight and artificial tanning devices-is the primary modifiable driver of rising melanoma and keratinocyte cancer rates across Europe, contributing to one of the largest burdens of UV-attributable cancer cases globally. Studies from 2024-2025 indicate that roughly 80-90% of melanomas in fair-skinned European populations are preventable through effective sun-protection campaigns, shade infrastructure, and stricter regulation of sun-beds, especially for adolescents.
Are there any regional prevention strategies showing concrete results?
Several European countries have demonstrated measurable reductions in melanoma growth rates after implementing integrated prevention packages, including Australia-style sun-safety school programs, mandatory sun-shade in public spaces, and bans on unsupervised sun-bed use. In Denmark and Sweden, for example, national campaigns launched in the early 2020s have coincided with a flattening of melanoma incidence in younger age groups under 35, even as rates remain elevated among older cohorts.
What does the data imply for future European policy?
Overall, the 2025 statistics point to an urgent need for a coordinated European skin cancer action plan, integrating national registries, harmonizing non-melanoma reporting, and standardizing early-detection guidelines across member states. Experts argue that without targeted investment in primary-care dermatology, teledermatology, and AI-assisted screening, Southern and Eastern Europe risk falling further behind Northern and Western neighbours in survival outcomes over the next decade.